Pharmaceuticals News and Research

RSS

IRIN examines intellectual property protection in South Africa

IRIN examines how patents and intellectual property protection in South Africa affects patients' access to medicines. "A form of intellectual property protection, patents are typically awarded to companies that can prove their product is new," IRIN writes, adding, "Not so in South Africa, say activists and researchers, who claim the country's patent system allows pharmaceutical companies to apply for new patents on existing drugs based on immaterial changes -- like adding table salt to a formulation or changing a pill's color."

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

FDA grants Priority Review to ImmunoGen’s trastuzumab emtansine BLA

ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Genentech, a member of the Roche Group, has disclosed that the U.S. Food and Drug Administration (FDA) has officially accepted the Biologics License Application (BLA) for trastuzumab emtansine and granted it Priority Review.

7 Nov 2012

Positive results from POZEN's PA32540 Phase 3 trials presented at AHA Scientific Sessions 2012

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results from two pivotal Phase 3 clinical trials of the investigational product, PA32540, at The American Heart Association (AHA) Scientific Sessions 2012, as Poster #12057: Treatment Continuation and Cardiovascular Safety of Antiplatelet Therapy with PA32540, A Tablet with Enteric-Coated Aspirin and Immediate-Release Omeprazole: Results of Two 6-Month, Phase 3 Studies.

6 Nov 2012

NAI receives U.S. patent allowance for sustained release beta-alanine products

Natural Alternatives International, Inc., a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance of its patent application directed to sustained release formulations of beta-alanine.

6 Nov 2012

Genetic testing valuable in determining etiology for childhood hearing loss

Genetic testing for a certain mutation in pediatric patients is valuable in determining a cause for unexplained hearing loss, according to a study in the November 2012 issue of Otolaryngology-Head and Neck Surgery.

6 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Virttu launches REPLICATE- Open Innovation Forum

Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced the launch of the Virttu REPLICATE- Open Innovation Forum.

6 Nov 2012

Depomed third quarter 2012 revenue increases to $33.3 million

Depomed, Inc. today reported financial results for the quarter and nine months ended September 30, 2012.

5 Nov 2012

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a second Phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer is being discontinued.

5 Nov 2012

Viewpoints: Romney, Obama offer details of their plans; The 'passionate supply-sider' who taught Paul Ryan; Medicare plan has not 'doomed GOP'

All presidential elections matter. This one matters a great deal. It matters to the senior who needs medical care but, thanks to ObamaCare, can't find a doctor who is taking new Medicare patients. ... This election is about them. It is about all of us. ... It is about the education of our children, the value of our homes, the take-home pay from our jobs, the price of the gasoline we buy, the choices we have in our health care.

5 Nov 2012

AcelRx commences dosing in ARX-04 sufentanil NanoTab Phase 2 study for acute and breakthrough pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has dosed the first subjects in a Phase 2, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate.

5 Nov 2012

Pradaxa use does not appear to increase serious bleeding

The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.

4 Nov 2012

New insight on ability of certain PAH-derived lesions to evade DNA repair machinery

A person doesn't have to go far to find a polycyclic aromatic hydrocarbon (PAH). These carcinogen precursors are inhaled through automobiles exhaust during the morning commute, are present in a drag of cigarette smoke, and are part of any barbequed meal.

4 Nov 2012

November issue of WHO Bulletin available online

The November issue of the WHO Bulletin features an editorial examining the need for a new model for pharmaceutical research, a public health news roundup, a research article examining parental perceptions surrounding polio immunization activities in Karachi, Pakistan, and a paper on the use of evidence to support healthy public policy, among others.

3 Nov 2012

Isis Pharmaceuticals to receive $1.25M from Pfizer for continued advancement of EXC 001

Isis Pharmaceuticals, Inc. announced today that it will receive a $1.25 million contingent payment from Pfizer Inc. triggered by Pfizer's decision to advance EXC 001 into a Phase 2 study.

3 Nov 2012

One-day seminar to explore ophthalmic innovations

The newest ophthalmic innovations with market potential will be the focus of a one-day seminar in Seattle on May 3, 2013 that will connect scientists, venture capitalists, pharmaceutical representatives and others.

3 Nov 2012

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).

3 Nov 2012

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

An international effort led by researchers at the Perelman School of Medicine at the University of Pennsylvania has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a rare and deadly cholesterol disorder.

3 Nov 2012

Pharmaceuticals News and Research

IRIN examines intellectual property protection in South Africa

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

FDA grants Priority Review to ImmunoGen’s trastuzumab emtansine BLA

Positive results from POZEN's PA32540 Phase 3 trials presented at AHA Scientific Sessions 2012

NAI receives U.S. patent allowance for sustained release beta-alanine products

Genetic testing valuable in determining etiology for childhood hearing loss

Alnylam third quarter 2012 revenues decrease to $16.8 million

Virttu launches REPLICATE- Open Innovation Forum

Depomed third quarter 2012 revenue increases to $33.3 million

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

Viewpoints: Romney, Obama offer details of their plans; The 'passionate supply-sider' who taught Paul Ryan; Medicare plan has not 'doomed GOP'

AcelRx commences dosing in ARX-04 sufentanil NanoTab Phase 2 study for acute and breakthrough pain

Pradaxa use does not appear to increase serious bleeding

New insight on ability of certain PAH-derived lesions to evade DNA repair machinery

November issue of WHO Bulletin available online

Isis Pharmaceuticals to receive $1.25M from Pfizer for continued advancement of EXC 001

One-day seminar to explore ophthalmic innovations

Bristol-Myers Squibb, Pfizer and Portola partner to conduct clinical study of PRT4445 and ELIQUIS

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence